[go: up one dir, main page]

WO1988009178A1 - Pharmaceutical preparation - Google Patents

Pharmaceutical preparation Download PDF

Info

Publication number
WO1988009178A1
WO1988009178A1 PCT/DE1988/000291 DE8800291W WO8809178A1 WO 1988009178 A1 WO1988009178 A1 WO 1988009178A1 DE 8800291 W DE8800291 W DE 8800291W WO 8809178 A1 WO8809178 A1 WO 8809178A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical
fructus
components
weight ratio
radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1988/000291
Other languages
German (de)
French (fr)
Inventor
Vladimir Badmajew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1988009178A1 publication Critical patent/WO1988009178A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)

Definitions

  • the invention relates to a pharmaceutical according to the preamble of claim 1 and to methods for using this pharmaceutical.
  • the pharmaceutical is predominantly, preferably exclusively, compressed from comminuted plant components.
  • the invention is based on the object of specifying a pharmaceutical which, owing to the special combination of its herbal active ingredients and substances, has improved therapeutic properties and is particularly suitable for the treatment of flu-like diseases and colds, in particular in their initial stages.
  • This pharmaceutical consists of dried (maximum, for example, 2% moisture content) vegetable constituents which are reduced to a powder (for example powder with particle sizes in the range 0.025 to 0.035 mm).
  • the constituents according to claim 1 are pressed together with any further constituents and any binding agents and / or lubricants to form a (dry) tablet, in particular a decoction tablet, or are located in an infusion bag, but other pharmaceutical dosage forms are not ruled out.
  • the therapeutic effect is based on the special combination of the six active ingredients. This combination has been shown to be effective in the treatment of febrile diseases, as are typically associated with flu and normal cold, but is not limited to this.
  • the active substances contained in the herbal components fight fever and general pain, firstly through an analgesic effect, secondly by facilitating the breathing process and clearing the airways, in particular relieving the cough and thirdly, an anti-inflammatory, decongestant and antiseptic effect, among other things the component Fructus Crataegi is responsible for this ⁇ have secondary diseases or caused by them.
  • the main property of the pharmaceutical according to the invention is that the body temperature is stabilized and regulated. Irregularities in body temperature, in particular disturbances in temperature regulation, as often occur during the transition seasons between summer and winter, are typically associated with a weakened resistance to virulent microorganisms. This can cause a viral and / or bacterial infection in the respiratory tract in the form of a normal cold, flu or pneumonia.
  • the pharmaceutical is particularly effective against colds and flu in the respective preliminary stages, before the full illness has developed. In these initial stages of the disease, patients often complain of sleepiness, weakness, pain, and shaking.
  • the pharmaceutical is not only suitable for combating the common cold in the earliest possible condition, but also for preventive therapy of these diseases, in particular for patients over the age of 60.
  • the pharmaceutical is also suitable for the therapy of sciatica, neuralgia and myalgia, i.e. muscle pain. It was found to be particularly interesting that the pharmaceutical also has a psychological effect and compensates for mental states in which the patients show depression or depression. It can be assumed that disturbances in the regulation of body temperature also have a psychological effect, namely as depression or depression, that there may be an interaction here.
  • Tablets are sufficiently stable that they can withstand the mechanical loads during normal handling, in particular, however, that the tablet is pressed through a blister pack, and also show sufficient mechanical long-term stability, but on the other hand they can dissolve very easily. This dissolution can occur either when swallowing or chewing, and it is desirable that the tablet at least partially dissolves in the mouth so that the taste of the components is already experienced when the pharmaceutical is swallowed. This is achieved in particular by allowing no coating to be used for the tablet. If the taste is experienced while swallowing, this contributes to the therapeutic effect and signals the medication to the patient.
  • the pharmaceutical preparation is again prepared dry and finely distributed in the form of packaging in an infusion bag, pressing is not necessary, but also not harmful.
  • the infusion bag is intended to enable easy removal of the (leached) plant components when the active substances are digested with liquid, without leaving a sentence that is annoying when drinking.
  • the infusion bag has the same function as normal tea, it is to avoid that a rest of the herbal preparation remains in the drink.
  • the prepared herbal tea it is proposed here to cook the prepared herbal tea until the amount of water used has shrunk to one third is, preferably one assumes a water quantity of three cups and wait until the water quantity has reduced to one cup.
  • a beaker or the like is added to the pharmaceutical, which has a corresponding line division.
  • the infusion bags preferably have a thread on which they can be pulled out of the hot brew after the tea has been prepared.
  • the prepared herbal tea should be drunk hot, at least warm.
  • the pharmaceutical described is administered in h ⁇ n ⁇ opathic doses, with homeopathic dosing of the exclusively herbal components generally being achieved in that the actual active ingredients are only present in very small amounts and the largest proportion of the herbal components Are fiber. These fibers in turn have a positive effect, for example on the digestive tract. The fiber stimulates it to function well and properly, which in turn is a good prerequisite for the absorption of the active ingredients.
  • Terminalia chebula (fructus) has a considerable amount of tannin, which can be between 20 and 45%, as well as gallic acid, it also contains antlirachinone compounds. Tannins are astringent and form a protective layer. In. Vitro experiments by the inventor have shown that Terminalia protects the epithelial cells against infections by influenza viruses.
  • Melia azadirachta contains camphor rhamnoglucoside and rutin. This medicinal plant is used in the pharmaceuticals because of its thermoregulating properties.
  • Crataegus oxycantha contains amydalin. This plant component can improve the blood circulation and positively influence the body temperature.
  • Gentiana radix
  • flavonuid gentisin gentisic acid
  • gentianose saccharides gentobiose and sucrose.
  • This herbal component is used in pharmaceuticals due to its temperature-regulating properties.
  • Euphrasia officinalis contains a special tannin called euphrasia tannic acid and mannitol.
  • the medicinal plant is used in the pharmaceuticals because of its thermoregulatory properties.
  • Pyrus cydonia contains mucilago, non-volatile oils and a small amount of cyanogenetic glycosides and an enzyme that affects its hydrolysis. This herbal component can regulate the body temperature in cases of hyperthermia.
  • Tussilago farfara (folia) contains tannic phytosterol and the alcohol Faradial. In vitro experiments with this medicinal plant by the inventor have shown that it can protect epithelial cells against infections by flu viruses.
  • Digestion of the plant parts of the pharmaceutical in boiling water has proven to be particularly suitable for preparing an effective medicine. This can be done by adding a certain amount of the vegetable constituents to water, for example a Einrarrmdekokt tablet in three cups of water (about 300 ml), it is boiled until the volume has reduced to the volume of a cup . The sediment should be removed, the remaining solution should still be drunk while hot. With a fully developed cold (flu), up to six tablets can be taken in this way. The dose should be reduced to one tablet a day during convalescence. For prevention, it is advisable to take the pharmaceutical up to twice a day, especially if there is a risk of infection with the flu virus.
  • a certain amount of the vegetable constituents for example a Einrarrmdekokt tablet in three cups of water (about 300 ml)
  • the sediment should be removed, the remaining solution should still be drunk while hot.
  • With a fully developed cold (flu) up to six tablets can be taken in this way.
  • the dose should
  • the decoction tablets can be replaced by infusion bags (tea bags) with lyophilic plant components.
  • infusion bags bag
  • lyophilic plant components A typical embodiment of a tablet weighing one gram is composed as follows:
  • Trigonella foenum-graecum (semen) 0.038 g
  • Hyssopus officinalis (herba) 0.019 g

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A pharmaceutical preparation consists mainly, and preferably exclusively, of comminuted plant components and minerals. It contains a combination of the six components: (I).

Description

Bezeichnung: Phaπnazeutikum Name: Phaπnazeikum

Die Erfindung bezieht sich auf ein Phaππazeutikum nach dem Oberbegriff des Anspruchs 1 sowie auf Verfahren zur Verwendung dieses Pharmazeuti- kums. Das Phaπnazeutikum ist vorwiegend, vorzugsweise ausschließlich aus zerkleinerten, pflanzlichen Bestandteilen zusammengepreßt.The invention relates to a pharmaceutical according to the preamble of claim 1 and to methods for using this pharmaceutical. The pharmaceutical is predominantly, preferably exclusively, compressed from comminuted plant components.

Der Erfindung liegt die Aufgabe zugrunde, ein Pharmazeutikum anzugeben, das aufgrund der speziellen Kombination seiner pflanzlichen Wirkbe¬ standteile und -stoffe verbesserte therapeutische Eigenschaften zeigt und insbesondere für die Behandlung von grippeartigen Krankheiten sowie Erkältungskrankheiten, insbesondere in deren Anfangsstadium, geeignet ist.The invention is based on the object of specifying a pharmaceutical which, owing to the special combination of its herbal active ingredients and substances, has improved therapeutic properties and is particularly suitable for the treatment of flu-like diseases and colds, in particular in their initial stages.

Diese Aufgabe wird gelöst durch ein Pharmazeutikum mit den Merkmalen des Patentanspruchs 1. .This object is achieved by a pharmaceutical with the features of claim 1.

Dieses Pharmazeutikum besteht aus getrockneten (maximal beispielsweise 2 % Feuchtigkeitsgehalt) pflanzlichen Bestandteilen, die zu einem Pulver (z. B. Puder mit Korngrößen im Bereich 0,025 bis 0,035 mm) zer¬ kleinert sind. Die Bestandteile gemäß Anspruch 1 sind zusammen mit gegebenenfalls weiteren Bestandteilen sowie eventuellen Binde- und/oder Gleitmitteln zu einer (trockenen) Tablette, insbesondere einer Dekokt- tablette, verpreßt oder befinden sich einem Aufgußbeutel, andere gale- nischen Darreichungsformen sind hierdurch jedoch nicht ausgeschlossen.This pharmaceutical consists of dried (maximum, for example, 2% moisture content) vegetable constituents which are reduced to a powder (for example powder with particle sizes in the range 0.025 to 0.035 mm). The constituents according to claim 1 are pressed together with any further constituents and any binding agents and / or lubricants to form a (dry) tablet, in particular a decoction tablet, or are located in an infusion bag, but other pharmaceutical dosage forms are not ruled out.

Die therapeutische Wirkung beruht auf der speziellen Kombination der sechs Wirkstoffe. Diese Kombination hat sich als wirksam bei der Be¬ handlung fiebriger Erkrankungen gezeigt, wie sie typischerweise mit Grippe und normaler Erkältung verbunden sind, ist aber hierauf nicht beschränkt. Die in den pflanzlichen Bestandteilen enthaltenen Wirksub¬ stanzen bekämpfen Fieber und allgemeine Schmerzen, dies erfolgt erstens durch eine analgetische Wirkung, zweitens durch Erleichterung des Atem¬ vorgangs und Befreiung der Atemwege, insbesondere Linderung des Hustens und drittens eine entzündungshenmende, -abschwellende und antiseptische Wirkung, hierfür ist unter anderem der Bestandteil Fructus Crataegi verantwortliche Das erfϋidungsgemäßβ Pharmazeutikum hat sich insbeson¬ dere als geeignet für ältere Menschen erwiesen, insbesondere Menschen über 60, die ein hohes Risiko an einer Grippe oder Erkältung nachfol¬ genden oder durch sie ausgelösten sekundären Erkrankungen haben.The therapeutic effect is based on the special combination of the six active ingredients. This combination has been shown to be effective in the treatment of febrile diseases, as are typically associated with flu and normal cold, but is not limited to this. The active substances contained in the herbal components fight fever and general pain, firstly through an analgesic effect, secondly by facilitating the breathing process and clearing the airways, in particular relieving the cough and thirdly, an anti-inflammatory, decongestant and antiseptic effect, among other things the component Fructus Crataegi is responsible for this ¬ have secondary diseases or caused by them.

Die Haupteigenschaft des erfindungsgemäßen Pharmazeutikums liegt darin, daß die Körpertemperatur stabilisiert und reguliert wird. Unregelmäßig¬ keiten der Körpertemperatur, insbesondere Störungen in der Te peratur- regulierung, wie sie häufig während der Übergangsjahreszeiten zwischen Sαπmer und Winter auftreten sind typischerweise mit einer geschwächten Widerstandsfähigkeit gegen virulente Mikroorganismen verbunden. Dadurch kann ein viraler und/oder bakterieller Infekt im Atmimgstrakt in Form einer normalen Erkältung, einer Grippe oder einer Lungenentzündung auftreten.The main property of the pharmaceutical according to the invention is that the body temperature is stabilized and regulated. Irregularities in body temperature, in particular disturbances in temperature regulation, as often occur during the transition seasons between summer and winter, are typically associated with a weakened resistance to virulent microorganisms. This can cause a viral and / or bacterial infection in the respiratory tract in the form of a normal cold, flu or pneumonia.

Das Phaπnazeutikum ist insbesondere wirksam gegen Erkältungskrankheiten und Grippe im jeweiligen Vorläuferstadium, bevor also die volle Krank--- heit sich, entwickelt hat. In diesen Anfangsstadien der Krankheiten klagen die Patienten häufig über Schläfrigkeit, Schwäche, Schmerzen und Schütteln. Das Pharmazeutikum eignet sich dabei nicht nur zur Bekäm¬ pfung der Erkältungskrankheiten in einem möglichst frühen Zustand, sondern auch zur präventiven Therapie dieser Krankheiten, insbesondere bei Patienten im Lebensalter über 60 Jahre. Das Phaπnazeutikum eignet sic auch zur Therapie von Sciatica, Neuralgien und Myalgien, also Muskelschmerzen. Als besonders interessant wurde festgestellt, daß das Phaπnazeutikum auch psychisch wirkt und Seelenzustände ausgleicht, bei denen die Patienten Niedergeschlagenheit oder Depressionen zeigen. Es ist wohl davon auszugehen, daß Störungen in der Regulierung in der Körpertemperatur sich auch seelisch auswirken, nämlich als Niederge¬ schlagenheit oder Depression, daß jedenfalls hier möglicherweise eine Wechselwirkung besteht.The pharmaceutical is particularly effective against colds and flu in the respective preliminary stages, before the full illness has developed. In these initial stages of the disease, patients often complain of sleepiness, weakness, pain, and shaking. The pharmaceutical is not only suitable for combating the common cold in the earliest possible condition, but also for preventive therapy of these diseases, in particular for patients over the age of 60. The pharmaceutical is also suitable for the therapy of sciatica, neuralgia and myalgia, i.e. muscle pain. It was found to be particularly interesting that the pharmaceutical also has a psychological effect and compensates for mental states in which the patients show depression or depression. It can be assumed that disturbances in the regulation of body temperature also have a psychological effect, namely as depression or depression, that there may be an interaction here.

Wenn das Pharmazeutikum aus feinpulverisierten pflanzlichen Bestandtei¬ len gemischt und trocken zu Tabletten verpreßt wird, so sind diese Tabletten einerseits so ausreichend stabil, daß sie den mechanischen Belastungen bei normaler Handhabung, insbesondere aber das Durchdrücken der Tablette durch eine Blisterpackung, aushalten und auch eine ausrei¬ chende mechanische Langzeitstabilität zeigen, andererseits aber sich sehr leicht auflösen können. Diese Auflösung kann entweder beim Schlucken bzw. Kauen auftreten, dabei ist erwünscht, daß sich die Tablette zumindest teilweise schon im Mund auflöst, so daß beim Schlucken des Pharmazeutikums bereits der Geschmack der Bestandteile erfahren wird. Dies wird insbesondere dadurch erreicht und ermöglicht, daß kein Überzug für die Tablette verwendet wird. Wenn der Geschmack bereits beim Schlucken erfahren wird, so trägt dies zur therapeutischen Wirkung bei und signalisiert dem Patienten das Medikament.If the pharmaceutical is mixed from finely pulverized herbal constituents and pressed dry into tablets, then these are Tablets, on the one hand, are sufficiently stable that they can withstand the mechanical loads during normal handling, in particular, however, that the tablet is pressed through a blister pack, and also show sufficient mechanical long-term stability, but on the other hand they can dissolve very easily. This dissolution can occur either when swallowing or chewing, and it is desirable that the tablet at least partially dissolves in the mouth so that the taste of the components is already experienced when the pharmaceutical is swallowed. This is achieved in particular by allowing no coating to be used for the tablet. If the taste is experienced while swallowing, this contributes to the therapeutic effect and signals the medication to the patient.

Wenn das Phaπnazeutikum dagegen wiederum trocken zubereitet und feinst verteilt in Form einer Verpackung in einem Aufgußbeutel angeboten wird, so ist eine Verpressung nicht notwendig, aber auch nicht schädlich. Der Aufgußbeutel soll dazu dienen, bei Flüssigkeitsaufschluß der Wirksub¬ stanzen ein einfaches Entfernen der (ausgelaugten) Pflanzehbestandteile zu ermöglichen, ohne daß ein beim Trinken störender Satz verbleibt. Insofern hat der Aufgußbeutel dieselbe Funktion wie bei normalem Tee, er soll vermeiden, daß ein Rest der pflanzlichen Zubereitung im Getränk verbleibt.If, on the other hand, the pharmaceutical preparation is again prepared dry and finely distributed in the form of packaging in an infusion bag, pressing is not necessary, but also not harmful. The infusion bag is intended to enable easy removal of the (leached) plant components when the active substances are digested with liquid, without leaving a sentence that is annoying when drinking. In this respect, the infusion bag has the same function as normal tea, it is to avoid that a rest of the herbal preparation remains in the drink.

Für eine besonders wirksame Zubereitung einer trinkfertigen Medizin hat sich ein Aufschluß der Wirkbestandteile in kochendem Wasser als sehr geeignet erwiesen. Hierzu wird eine vorgegebene Menge der Pflanzenbe¬ standteile, wie sie beispielsweise im später beschriebenen Ausführungs¬ beispiel mengenmäßig angegeben ist, und z. B. in Form einer Dekoktta- blette vorliegt oder sich in einem Aufgußbeutel befindet, in Wasser gegeben oder mit Wasser übergössen. Das Wasser wird zum Kochen ge¬ bracht. Man kann nun einerseits die Zeitdauer des Kochens vorgeben und abmessen, andererseits aber auch über den Wasserverlust, der beim Kochen zwangsläufig auftritt, die für das Auslaugen der Wirkbestand- teile notwendige Zeitdauer vorgeben. Hier wird in bevorzugter Ausfüh¬ rung der Erfindung vorgeschlagen, den zubereiteten Kräutertee solange zu kochen, bis die eingesetzte Wassermenge auf ein Drittel geschrumpft ist, vorzugsweise geht man von einer Wassermenge von drei Tassen aus und warten, bis sich die Wassermenge auf eine Tasse reduziert hat. In Weiterbildung der Erfindung wird dem Pharmazeutikum ein Becherglas oder dergleichen zugefügt, das eine entsprechende Strichteilung hat. Die Aufgußbeutel haben vorzugsweise einen Faden, an dem sie nach Zuberei¬ tung des Tees aus dem heißen Gebräu herausgezogen werden können. Der zubereitete Kräutertee soll heiß, zumindest warm, getrunken werden.For a particularly effective preparation of a ready-to-drink medicine, digestion of the active ingredients in boiling water has proven to be very suitable. For this purpose, a predetermined amount of the plant components, as specified in terms of quantity, for example in the embodiment described later, is added, and z. B. is in the form of a decoction tablet or is in an infusion bag, placed in water or poured with water. The water is brought to a boil. One can now specify and measure the duration of the cooking on the one hand, and on the other hand also specify the time required for the leaching out of the active ingredients via the water loss that inevitably occurs during cooking. In a preferred embodiment of the invention it is proposed here to cook the prepared herbal tea until the amount of water used has shrunk to one third is, preferably one assumes a water quantity of three cups and wait until the water quantity has reduced to one cup. In a further development of the invention, a beaker or the like is added to the pharmaceutical, which has a corresponding line division. The infusion bags preferably have a thread on which they can be pulled out of the hot brew after the tea has been prepared. The prepared herbal tea should be drunk hot, at least warm.

Die Verabreichung des beschriebenen Pharmazeutikums erfolgt in hαnδo- pathischen Dosen, wobei einer homöopathische Dosierung bei den aus¬ schließlich pflanzlichen Bestandteilen schon dadurch im allgemeinen erzielt wird, daß in diesen die eigentlichen Wirkstoffe nur in sehr geringen Mengen vorhanden sind und der größte Anteil der pflanzlichen Bestandteile Baiaststoffe sind. Diese Baiaststoffe haben wiederum einen positiven Effekt beispielsweise auf den Verdauungstrakt. Durch die Balaststoffc wird dieser zu einer guten und ordnungsgemäßen Funktion angeregt, wodurch wiederum eine gute Voraussetzung für die Aufnahme der Wirkstoffe gegeben ist.The pharmaceutical described is administered in hαnδopathic doses, with homeopathic dosing of the exclusively herbal components generally being achieved in that the actual active ingredients are only present in very small amounts and the largest proportion of the herbal components Are fiber. These fibers in turn have a positive effect, for example on the digestive tract. The fiber stimulates it to function well and properly, which in turn is a good prerequisite for the absorption of the active ingredients.

Die therapeutische Wirkung wird durch die Kombination der folgenden Bestandteile erzielt:The therapeutic effect is achieved by combining the following components:

Terminalia chebula (fructus) hat einen beträchtlichen Anteil an Tannin, der zwischen 20 und 45 % liegen kann, sowie an Gallussäure, es enhält auch Antlirachinon-Verbindungen. Tannine sind adstringierend und bilden eine schützende Schicht. In. vitro-Experimente des Erfinders haben ge¬ zeigt, daß Terminalia die Epithelzellen gegen Infektionen durch Grippe¬ viren schützt.Terminalia chebula (fructus) has a considerable amount of tannin, which can be between 20 and 45%, as well as gallic acid, it also contains antlirachinone compounds. Tannins are astringent and form a protective layer. In. Vitro experiments by the inventor have shown that Terminalia protects the epithelial cells against infections by influenza viruses.

Melia azadirachta (fructus) enthält Kampferol-Rhamnoglucosid und Rutin. Im Phaπnazeutikum wird diese Heilpflanze wegen ihrer thermoregulieren- den Eigenschaften eingesetzt.Melia azadirachta (fructus) contains camphor rhamnoglucoside and rutin. This medicinal plant is used in the pharmaceuticals because of its thermoregulating properties.

Crataegus oxycantha (fructus) enthält Amydalin. Dieser Pflanzenbestand¬ teil kann die Blutzirkulation verbessern und die Körpertemperatur posi¬ tiv beeinflussen. Gentiana (radix) enthält Flavonuid-Gentisin, Gentisinsäure, Gentianose- Saccharide, Gentobiose und Saccharose. Dieser pflanzliche Bestandteil wird im Pharmazeutikum aufgrund seiner temperaturregulierenden Eigen¬ schaften eingesetzt.Crataegus oxycantha (fructus) contains amydalin. This plant component can improve the blood circulation and positively influence the body temperature. Gentiana (radix) contains flavonuid gentisin, gentisic acid, gentianose saccharides, gentobiose and sucrose. This herbal component is used in pharmaceuticals due to its temperature-regulating properties.

Euphrasia officinalis (herba) enthält ein spezielles Tannin, das Euphrasia-Tanninsäure genannt wird und Mannit. Im Phaπnazeutikum wird die Heilpflanze wegen ihrer theπnoregulierenden Eigenschaft eingesetzt.Euphrasia officinalis (herba) contains a special tannin called euphrasia tannic acid and mannitol. The medicinal plant is used in the pharmaceuticals because of its thermoregulatory properties.

Pyrus cydonia (semen) enthält Mucilago, nicht flüchtige Öle sowie eine geringe Menge an cyanogenetischen Glycosiden und ein Enzym, das seine Hydrolyse beeinflußt. Dieser pflanzliche Bestandteil kann die Körper¬ temperatur in Fällen von Hyperthe mie regulieren.Pyrus cydonia (semen) contains mucilago, non-volatile oils and a small amount of cyanogenetic glycosides and an enzyme that affects its hydrolysis. This herbal component can regulate the body temperature in cases of hyperthermia.

Tussilago farfara (folia) enthält tannisches Phytosterol und den Alko¬ hol Färadial. In vitro-Experimente mit dieser Heilpflanze durch den Erfinder haben gezeigt, daß sie Epithelzellen gegen Infektionen durch Grippeviren schützen kann.Tussilago farfara (folia) contains tannic phytosterol and the alcohol Faradial. In vitro experiments with this medicinal plant by the inventor have shown that it can protect epithelial cells against infections by flu viruses.

Der Aufschluß der pflanzlichen Teile des Pharmazeutikums in kochendem Wasser hat sich als besonders geeignet erwiesen, um eine wirksame Medizin zu bereiten. Dies kann dadurch erfolgen, daß eine bestimmte Menge der pflanzlichen Bestandteile in Wasser gegeben wird, beispiels¬ weise eine Eingrarrmdekokt-Tablette in drei Tassen Wasser (etwa 300 ml) , es wird solange gekocht, bis sich das Volumen auf das Volumen einer Tasse reduziert hat. Das Sediment sollte entfernt werden, die verblie¬ bene Lösung sollte noch im heißen Zustand getrunken werden. Bei voll entwickelter Erkältung (Grippe) können bis zu sechs Tabletten so einge¬ nommen werden. Die Dosis sollte auf eine Tablette pro Tag während der Rekonvaleszenz verringert werden. Für eine Vorbeugung empfiehlt es sich, das Phaπnazeutikum bis zu zweimal pro Tag einzunehmen, insbeson¬ dere dann, wenn ein Risiko der Infektion mit Grippeviren besteht.Digestion of the plant parts of the pharmaceutical in boiling water has proven to be particularly suitable for preparing an effective medicine. This can be done by adding a certain amount of the vegetable constituents to water, for example a Einrarrmdekokt tablet in three cups of water (about 300 ml), it is boiled until the volume has reduced to the volume of a cup . The sediment should be removed, the remaining solution should still be drunk while hot. With a fully developed cold (flu), up to six tablets can be taken in this way. The dose should be reduced to one tablet a day during convalescence. For prevention, it is advisable to take the pharmaceutical up to twice a day, especially if there is a risk of infection with the flu virus.

In einer Weiterbildung der Erfindung können die Dekokt-Tabletten er¬ setzt werden durch Infusionsbeutel (Teebeutel) mit lyophilen Pflanzen¬ bestandteilen. Ein typisches Ausführungsbeispiel einer Tablette mit dem Gewicht von einem Gramm ist wie folgt zusammengesetzt:In a further development of the invention, the decoction tablets can be replaced by infusion bags (tea bags) with lyophilic plant components. A typical embodiment of a tablet weighing one gram is composed as follows:

Botanischer Name Teil der Pflanze Dosis pro TabletteBotanical name part of the plant dose per tablet

1. Terminalia chebula (fructus) 0,075 g1. Terminalia chebula (fructus) 0.075 g

2. Melia azadirachta (fructus) 0,075 g2. Melia azadirachta (fructus) 0.075 g

3. Crataegus oxycanthus (fructus) 0, 075 g3. Crataegus oxycanthus (fructus) 0.075 g

4. Gentiana barbata (radix) 0,038 g4. Gentiana barbata (radix) 0.038 g

5. Euphrasia officinalis (folia) 0,038 g5. Euphrasia officinalis (folia) 0.038 g

6. Pyrus cydonia - (semen) 0,075 g6. Pyrus cydonia - (semen) 0.075 g

7. Tussilago farfarae (folia) 0,019 g7. Tussilago farfarae (folia) 0.019 g

8. Robinia (radix) 0, 113 g8. Robinia (radix) 0.13 g

9. Akebia quinata (radix) 0,075 g9. Akebia quinata (radix) 0.075 g

10. Angelica archangelica (radix) 0,038 g10. Angelica archangelica (radix) 0.038 g

11. Hel-ianthus annuus (flores) 0, 038 g11. Hel-ianthus annuus (flores) 0.038 g

12. Trigonella foenum- graecum . (semen) 0,038 g12. Trigonella foenum-graecum. (semen) 0.038 g

13. Galeopsis ochroleuca (herba) 0,019 g13. Galeopsis ochroleuca (herba) 0.019 g

14. Primula veris (herba) 0, 019 g14. Primula veris (herba) 0.019 g

15. Cinchona (cortex) 0, 019 g15. Cinchona (cortex) 0.019 g

16. Sa buca nigra (flores) 0, 019 g16. Sa buca nigra (flores) 0.019 g

17. Matricaria chamcmilla (flores) 0, 019 g17. Matricaria chamcmilla (flores) 0.019 g

18; Salix alba (cortex) 0,019 g18; Salix alba (cortex) 0.019 g

19. Hyssopus officinalis (herba) 0,019 g19. Hyssopus officinalis (herba) 0.019 g

20. Adiantum Capillae veneris (herba) 0, 019 g20. Adiantum Capillae veneris (herba) 0.019 g

21. Enula Helenium (radix) 0, 075 g21. Enula helenium (radix) 0.075 g

22. Aquilegia viridifolia (herba) 0,004 g22. Aquilegia viridifolia (herba) 0.004 g

23. . Althea officinalis (radix) 0, 025 g 23rd Althea officinalis (radix) 0.025 g

Claims

A n s p r ü c h e Expectations 1. Phaπnazeutikum, das vorwiegend, vorzugsweise ausschließlich, aus zerkleinerten, pflanzlichen Bestandteilen und Mineralien zusam¬ mengesetzt ist, dadurch gekennzeichnet, daß es folgende sechs Be¬ standteile in Kombination aufweist:1. Pharmaceutical, which is predominantly, preferably exclusively, composed of comminuted, vegetable components and minerals, characterized in that it has the following six components in combination: Botanischer Name Teil der Pflanze FamilieBotanical name part of the plant family 1. Terminalia chebulae (fructus) Cαnbretaceae1. Terminalia chebulae (fructus) Cαnbretaceae 2. Melia azadirachta (fructus) Meliaceae2. Melia azadirachta (fructus) Meliaceae 3. Crataegus oxycantha (fructus) Rosaceae3. Crataegus oxycantha (fructus) Rosaceae 4. Gentiana barbata (radix) Gentianaceae4. Gentiana barbata (radix) Gentianaceae 5. Euphräsia officinalis (herba) Scrophulariaceae5. Euphräsia officinalis (herba) Scrophulariaceae 6. Pyrus cydonia (semen) Rosaceae.6. Pyrus cydonia (semen) Rosaceae. 2. Phaπnazeutikum nach Anspruch 1, dadurch gekennzeichnet, daß es als zusätzlichen Bestandteile Tussilago farfara (folia) aus der Familie der Compositae enthält.2. Phaπnazeutikum according to claim 1, characterized in that it contains Tussilago farfara (folia) from the family of Compositae as additional components. 3. Pharmazeutikum nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß es die Bestandteil Terminalia chebulae (fructus) , Melia azadirachta (fructus) , Crataegus oxycantha (fructus) , Gentiana barbata (radix) , Euphräsia officinalis (herba) und Pyrus cydonia (semen) im Gewichtsverhältnis zwei zu zwei zu zwei zu eins zu eins bis zwei zu zwei enthält, wobei Euphräsia vorzugsweise im Gewichtsverhältnis eins vorliegt.3. Pharmaceutical according to claim 1 or 2, characterized in that it contains the component Terminalia chebulae (fructus), Melia azadirachta (fructus), Crataegus oxycantha (fructus), Gentiana barbata (radix), Euphräsia officinalis (herba) and Pyrus cydonia (semen ) contains two to two to two to one to one to two to two in a weight ratio, Euphräsia preferably being in a weight ratio of one. 4. Pharmazeutikum nach einem der Ansprüche 1 bis 3, dadurch gekenn¬ zeichnet, daß Tussilago farfara (folia) im relativen Gewichtsverhältnis von Null Komma fünf vorliegt.4. Pharmaceutical according to one of claims 1 to 3, characterized gekenn¬ characterized in that Tussilago farfara (folia) is present in a relative weight ratio of zero point five. 5. Pharmazeutikum nach einem der Ansprüche 1 bis 4, dadurch gekenn- zeichnet, daß es als zusätzlichen Bestandteil Rubina (radix) und/oder Akebia Quinata (radix) aufweist.5. Pharmaceutical according to one of claims 1 to 4, characterized records that it has Rubina (radix) and / or Akebia Quinata (radix) as an additional component. 6. Pharmazeutikum nach Anspruch 5, dadurch gekenn¬ zeichnet, daß Rubinia im relativen Gewichtsverhältnis von vier und/oder Akebia im relativen Gewichtsverhältnis von zwei vorliegt.6. Pharmaceutical according to claim 5, characterized gekenn¬ characterized in that Rubinia is present in the relative weight ratio of four and / or Akebia in the relative weight ratio of two. 7. Pharmazeutikum nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, daß es ausschließlich aus getrockneten, pulverisierten Pflanzenbestandteilen zusammengesetzt ist.7. Pharmaceutical according to one of claims 1 to 6, characterized in that it is composed exclusively of dried, pulverized plant components. 8. Phaπnazeutikum nach einem der Ansprüche 1 bis 7, dadurch gekenn¬ zeichnet, daß die Bestandteile zu Tabletten verpreßt sind, die vorzugsweise keinen Überzug haben und/oder denen vorzugsweise ein Binde- oder Gleitmittel zugegeben ist.8. Pharmaceutical according to one of claims 1 to 7, characterized gekenn¬ characterized in that the components are pressed into tablets, which preferably have no coating and / or to which a binder or lubricant is preferably added. 9. Pharmazeutikum nach einem der Ansprüche 1 bis 7, dadurch gekenn¬ zeichnet, daß sich das Gemisch der Bestandteile in einem wasser¬ durchlässigen Aufgußbeutel befindet.9. Pharmaceutical according to one of claims 1 to 7, characterized gekenn¬ characterized in that the mixture of ingredients is in a water permeable infusion bag. 10. Zubereitung einer teeähnlichen, eirinahmefertigen Arznei auf der Basis des Pharmazeutikums nach den Ansprüchen 8 oder'9, dadurch gekennzeichnet, daß der abgepackten Menge des Pharmazeutikums in Form einer Tablette oder eines gefüllten Aufgußbeutels Wasser zuge¬ fügt und aufgekocht wird.10. Preparation of a tea-like, eirinahmefertigen drug on the basis of the pharmaceutical agent according to claims 8 or '9, characterized in that the packed amount of the pharmaceutical in the form of a tablet or adds a filled infusion bag and zuge¬ water is boiled. 11. Verfahren nach Anspruch 10, dadurch gekennzeichnet, daß 300 ml Wasser verwendet wird und solange gekocht wird, bis die Wassermenge auf 100 ml verringert ist.11. The method according to claim 10, characterized in that 300 ml of water is used and boiled until the amount of water is reduced to 100 ml. 12. Verwendung des Pharmazeutikums nach einem der Ansprüche 1 bis 11 zur Therapie der Thermoregulation in Fällen von12. Use of the pharmaceutical according to one of claims 1 to 11 for the therapy of thermoregulation in cases of Unter- oder Übertemperatur (Hypo- und Hyperthermia) , insbesondere bei Infektionen des unteren und oberen Atemapparates, z. B. Grippe, Erkältung. Under or over temperature (hypothermia and hyperthermia), especially in infections of the lower and upper respiratory system, e.g. B. flu, cold.
PCT/DE1988/000291 1987-05-18 1988-05-17 Pharmaceutical preparation Ceased WO1988009178A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3716622 1987-05-18
DEP3716622.0 1987-05-18

Publications (1)

Publication Number Publication Date
WO1988009178A1 true WO1988009178A1 (en) 1988-12-01

Family

ID=6327800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1988/000291 Ceased WO1988009178A1 (en) 1987-05-18 1988-05-17 Pharmaceutical preparation

Country Status (1)

Country Link
WO (1) WO1988009178A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657169A1 (en) * 1993-12-06 1995-06-14 The Nikka Whisky Distilling Co., Ltd. Fruit polyphenol; process for production thereof; and antioxidant, hypotensive agent, antimutagenic agent, antiallergic agent and anticariogenic agent, each comprising said polyphenol
US8043634B2 (en) 2006-03-28 2011-10-25 Klaus Huber Drug and/or food supplement containing NISYLEN, Cepa, Euphrasia, Belladonna and/or Mercurius solubilis
EP2441333A1 (en) * 2010-10-14 2012-04-18 Schaper & Brümmer Gmbh & Co. Kg Chewable tablet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145211A1 (en) * 1970-09-10 1972-03-16 Akademia Medyczna W Warszawie, Warschau Hypotonic and sedative medicament - from hawthorn extract freed from lipoids and low mw phenols
JPS5748922A (en) * 1980-09-08 1982-03-20 Terumo Corp Antibacterial agent
SU979701A2 (en) * 1981-06-29 1982-12-07 Предприятие П/Я В-2504 Pump testing stand
FR2557797A1 (en) * 1984-01-09 1985-07-12 Cheikho Zahira Terminalia chebula-based therapeutic composition for the oral treatment of psoriasis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145211A1 (en) * 1970-09-10 1972-03-16 Akademia Medyczna W Warszawie, Warschau Hypotonic and sedative medicament - from hawthorn extract freed from lipoids and low mw phenols
JPS5748922A (en) * 1980-09-08 1982-03-20 Terumo Corp Antibacterial agent
SU979701A2 (en) * 1981-06-29 1982-12-07 Предприятие П/Я В-2504 Pump testing stand
FR2557797A1 (en) * 1984-01-09 1985-07-12 Cheikho Zahira Terminalia chebula-based therapeutic composition for the oral treatment of psoriasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Patent Abstracts of Japan, Band 6, Nr. 122 (C-112)[1000], 7. Juli 1982; & JP,A,57 048 922 (TERUMO K.K.) 20 Marz 1982 *
Soviet Inventions Illustrated, Woche K08, 6. April 1983, & SU,A,979 701 (AS SIBE BURYA BRANC) 23. April 1982 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU683892B2 (en) * 1993-02-22 1997-11-27 Asahi Group Holdings, Ltd. Fruit polyphenol, production and uses thereof
EP0657169A1 (en) * 1993-12-06 1995-06-14 The Nikka Whisky Distilling Co., Ltd. Fruit polyphenol; process for production thereof; and antioxidant, hypotensive agent, antimutagenic agent, antiallergic agent and anticariogenic agent, each comprising said polyphenol
US5994413A (en) * 1993-12-06 1999-11-30 The Nikka Whisky Distilling Co., Ltd. Process for the production of fruit polyphenols from unripe rosaceae fruit
CN1051089C (en) * 1993-12-06 2000-04-05 日加威士己株式会社 Fruit polyphenol process for production thereof, and antioxidant, hypotensive agent, antimutagenic agent, antiallergic agent and anticariogenic agent each comprising said polyphenol
US8043634B2 (en) 2006-03-28 2011-10-25 Klaus Huber Drug and/or food supplement containing NISYLEN, Cepa, Euphrasia, Belladonna and/or Mercurius solubilis
EP2441333A1 (en) * 2010-10-14 2012-04-18 Schaper & Brümmer Gmbh & Co. Kg Chewable tablet
EP2441333B1 (en) 2010-10-14 2016-05-04 Schaper & Brümmer Gmbh & Co. Kg Chewable tablet

Similar Documents

Publication Publication Date Title
Ahmad et al. Medicinal plants used by Kadazandusun communities around Crocker Range
Selvam Inventory of vegetable crude drug samples housed in botanical survey of India, Howrah
CN1031186A (en) The prescription and the facture of specially good effect bony spur antiphlogistine
DE3705151A1 (en) WARTS
CN101987123A (en) Medicament for easing pain of human body and preparation method thereof
CN100402043C (en) Bagged Chinese medicine pieces prepared for decoction and its preparation method
CN1196948A (en) Full presciption medicine for treating rheumatism disease
DE202004018534U1 (en) Herbal composition for side-effect free treatment of depression, comprising herbs or herbal extracts for promoting blood flow and reducing coagulated blood levels, calming, sedation and flow of Qi
US5603935A (en) Composition for the treatment of snoring and methods of use thereof
CN101284084A (en) Externally used Chinese medicine for curing hyperosteogeny and protrusion of lumbar intervertebral discs
WO1988009178A1 (en) Pharmaceutical preparation
DE112014006651T5 (en) Pharmaceutical composition and its use for controlling the blood lipids and body weight of a human body
CN101380452A (en) Preparation method of no-alcohol type Shexiang Qushu liquid oral preparation
CN111956770A (en) Quick-acting spray for treating cervical spondylosis and preparation process thereof
AU2004229119A1 (en) Herbal composition
CN1985921B (en) Chinese medicine composition for treating common cold and its preparing method
CN112043760B (en) Traditional Chinese medicine composition for treating gill rot disease of freshwater fish and preparation method thereof
RU2043114C1 (en) Method for preparing and applying species of medicinal herbes
CN100512796C (en) Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method
CN1686424B (en) A pharmaceutical composition containing Scutellaria baicalensis and Bupleurum bupleuri and its preparation method
CN116262129B (en) Traditional Chinese veterinary medicine composition for treating skin itch and preparation method thereof
Sharma et al. An Advance Innovation of Dosage Form of Ayurveda
CN110141656A (en) A kind of Fuke Tiaojing blood-nourishing Chinese medicine composition and preparation method thereof
CN102824619A (en) Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method thereof
CN106177891A (en) A kind of Chinese medicine composition and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE